• home
  • > Promotion Center >
  • News

새소식 차메디텍의 새로운 소식을 전달하고 있습니다.

CHABio&Diostech signs an exclusive licensing contract with placental stem cell therapy product development company, ‘Pluristem’
Date 2013-06-28 Hit 1028

CHABio&Diostech signs an exclusive licensing contract with placental stem cell therapy product development company, ‘Pluistem’

-Plans to establish joint venture with Pluristem in the near future
-Strategic alliance on exchanging stocks with Pluristem Therapeautics
-Great hope for patients with incurable peripheral artery disease when commercialized

CHABio&Diostech has announced that they have entered into an exclusive licensing contract on PLX(Placental eXpanded) therapy product with Pluristem Therapeautics. Placental derived cell therapy product developed by Pluristem is currently on the clinical trial for the patients with critical leg ischemia or intermittent claudication in US and Germany. First phase of clinical trial has proven its stability.

Through this agreement, CHABio&Diostech acquired exclusive right of contract regarding placental stem cell therapy product in Korea. They have agreed that clinical data produced in Korea can be also used by other countries and they will establish a joint venture to commercialize their products. In order to intensify strategic partnership, they will exchange 10million stocks each.

According to CHABio&Diostech, the existing few stem cell therapy products not only have high prices but also have difficult surgical procedures. However, this placental stem cell therapy product for critical leg ischemia and intermittent claudication can be simply applied by injections and have price competitiveness as mass production is possible.

Representative of CHABio&Diostech has mentioned as “As this partnership is the first example of importing foreign pipeline by using CHABio&Diostech’s advantageous position in Korea, it will provide great strategic opportunities for various cell therapy products to make inroads into Korea and Asian markets.”

CHABio&Diostech’s strategic partner Pluristem, listed on NASDAQ,, is a 100% affiliated company of Pluristem Therapeautics that has leading-edge technology regarding placental derived mesenchymal cell or 3Dcell cultivation system.


Forward-Looking Statements
Certain statements contained herein constitute forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “anticipates,” “plans,” “estimates,” “expects” and variations of these words and similar expressions are intended to identify forward-looking statements. Such statements address future financial results and business standings. Forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties, which are affected by further changes in business environment. Therefore, actual future results and trends may differ materially from the forecasts reflected in the forward-looking statements herein due to a variety of factors such as changes in market conditions and strategy revisions. The company does not undertake any legal obligation to present any supporting evidence against investment results of investors under any circumstances.

 

Attachment
Next CHA Bio&Diostech conducts Korea’s first human clinical trial using embryonic stem cells to treat retina degeneration.
Previous CHA Bio&Diostech conducts Korea′s first human clinical trial using embryonic stem cells to treat Stargardt′ macular dystrophy (SMD)
목록